

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 39314

**Title:** Era of direct acting anti-viral agents for the treatment of hepatitis C

**Reviewer's code:** 02937613

**Reviewer's country:** Canada

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2018-04-11

**Date reviewed:** 2018-04-17

**Review time:** 6 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

Looks good to me. It is clearly written. I was unclear what the source of the drug-drug interactions is. I was also unclear where the treatment protocols were derived. The review could be improved perhaps by adding a statement about this at the end of the introduction or adding a brief methods section, depending on how simple



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

or complex the author's response.

#### INITIAL REVIEW OF THE MANUSCRIPT

##### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

##### *BPG Search:*

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 39314

**Title:** Era of direct acting anti-viral agents for the treatment of hepatitis C

**Reviewer's code:** 02528523

**Reviewer's country:** Mexico

**Science editor:** Fang-Fang Ji

**Date sent for review:** 2018-04-11

**Date reviewed:** 2018-04-22

**Review time:** 11 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input checked="" type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

Present manuscript is an interesting summary of the new treatments of HCV infection. It has updated information on the application of several combinations of drugs, as well as other relevant data on their interactions with other drugs and side effects. However, there are some comments and suggestions that need to be added to this manuscript

before recommending accepting it for publication. It is necessary to mention the meanings of each abbreviation at its first mention (for example, SVR12, GFR). On page 7, you must specify that CC and TT is a reference to which polymorphism. The first drugs mentioned in the text are protease inhibitors, so a list of them is made before proceeding to describe them. On page 7, it would appear that sofosbuvir is a protease inhibitor as well, since it has not been mentioned before in the text. The same happens with ombitasvir on page 10, with elbasvir on page 13, and after there are others. The text on page 10, lines 4 through 9 have no references. The same applies to the text on pages 12 and 15. Also page 14, last paragraph. Pages 17-19 do not present references. The text on page 21 either. On page 22, lines 6-14. All sections "Drug-drug interaction" do not present references. Posology and other data presented at the end have no references. The list of drugs on page 36 should be a table. The indications for treatment described between pages 38 to 50, should probably be in tables for better understanding. As they are, they have non-homogeneous formats, since in some parts they appear as tables and in others they do not. In this part, references are not present either. In the section HCV / HIV Co-infection, the sources of information are almost not mentioned. In the HCV section in post-liver transplant patients, the data mentioned in several tables should be one. Likewise, the sources are not mentioned. It would be important to add some more accurate data on the resistance to AASD (resistance-associated substitutions). There are several writing errors in the entire manuscript that have to be corrected.

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- [ ] The same title
- [ ] Duplicate publication
- [ ] Plagiarism



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

[Y] No

***BPG Search:***

[ ] The same title

[ ] Duplicate publication

[ ] Plagiarism

[Y] No